Insulet - PODD Stock Forecast, Price & News

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. It offers Omnipod System, a self-adhesive disposable tubeless Omnipod device that is worn on the body for up to three days at a time, as well as its wireless companion, the handheld personal diabetes manager. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, the Middle East, and Australia. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.

Analysts Set New Price Targets

Several equities analysts recently commented on the company. Canaccord Genuity Group boosted their target price on Insulet from $250.00 to $290.00 and gave the stock a "buy" rating in a research report on Friday. Morgan Stanley reduced their target price on Insulet from $268.00 to $244.00 and set an "equal weight" rating for the company in a research report on Tuesday, June 7th. BTIG Research reduced their target price on Insulet from $310.00 to $250.00 and set a "buy" rating for the company in a research report on Friday, June 24th. Raymond James boosted their target price on Insulet from $262.00 to $280.00 in a research report on Friday. Finally, Citigroup cut Insulet from a "buy" rating to a "neutral" rating and reduced their target price for the stock from $310.00 to $250.00 in a research report on Monday, July 11th. Four analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. Based on data from MarketBeat.com, Insulet currently has an average rating of "Moderate Buy" and an average price target of $289.50.

Insulet Trading Up 4.3 %

Shares of NASDAQ:PODD traded up $11.04 during midday trading on Friday, reaching $267.05. The company had a trading volume of 833,891 shares, compared to its average volume of 422,491. Insulet has a one year low of $181.00 and a one year high of $324.81. The company has a quick ratio of 4.51, a current ratio of 5.98 and a debt-to-equity ratio of 3.11. The firm's fifty day moving average price is $227.06 and its 200-day moving average price is $235.78. The stock has a market cap of $18.52 billion, a PE ratio of 534.10 and a beta of 0.73.

Insulet (NASDAQ:PODD - Get Rating) last released its earnings results on Thursday, August 4th. The medical instruments supplier reported ($0.50) earnings per share for the quarter, missing analysts' consensus estimates of $0.22 by ($0.72). The company had revenue of $299.40 million during the quarter, compared to the consensus estimate of $290.87 million. Insulet had a net margin of 2.94% and a return on equity of 13.29%. The company's revenue was up 13.8% on a year-over-year basis. During the same period last year, the firm posted $0.10 EPS. On average, equities research analysts anticipate that Insulet will post 1.3 earnings per share for the current year.

Insider Buying and Selling at Insulet

In other Insulet news, Director Shacey Petrovic sold 15,000 shares of the company's stock in a transaction that occurred on Friday, July 1st. The stock was sold at an average price of $222.90, for a total transaction of $3,343,500.00. Following the completion of the transaction, the director now owns 13,695 shares of the company's stock, valued at approximately $3,052,615.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In other Insulet news, Director Shacey Petrovic sold 15,000 shares of the company's stock in a transaction that occurred on Friday, July 1st. The stock was sold at an average price of $222.90, for a total transaction of $3,343,500.00. Following the completion of the transaction, the director now owns 13,695 shares of the company's stock, valued at approximately $3,052,615.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, COO Charles Alpuche sold 6,000 shares of the company's stock in a transaction that occurred on Monday, June 6th. The shares were sold at an average price of $215.32, for a total value of $1,291,920.00. Following the transaction, the chief operating officer now directly owns 43,899 shares of the company's stock, valued at approximately $9,452,332.68. The disclosure for this sale can be found here. 0.90% of the stock is currently owned by corporate insiders.